{"id":209514,"date":"2026-02-03T09:10:00","date_gmt":"2026-02-03T14:10:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/02\/03\/ocumetics-reports-positive-three-month-first-in-human-results-significantly-de-risking-its-accommodating-intraocular-lens-technology\/"},"modified":"2026-02-03T09:30:10","modified_gmt":"2026-02-03T14:30:10","slug":"ocumetics-reports-positive-three-month-first-in-human-results-significantly-de-risking-its-accommodating-intraocular-lens-technology","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/02\/03\/ocumetics-reports-positive-three-month-first-in-human-results-significantly-de-risking-its-accommodating-intraocular-lens-technology\/","title":{"rendered":"Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology"},"content":{"rendered":"<p><a href=\"https:\/\/investingnews.com\/ocumetics-reports-positive-three-month-first-in-human-results-significantly-de-risking-its-accommodating-intraocular-lens-technology\/\">Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology<\/a><\/p>\n<p><a href=\"https:\/\/investingnews.com\/ocumetics-reports-positive-three-month-first-in-human-results-significantly-de-risking-its-accommodating-intraocular-lens-technology\/\">https:\/\/investingnews.com\/ocumetics-reports-positive-three-month-first-in-human-results-significantly-de-risking-its-accommodating-intraocular-lens-technology\/<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-02-03 09:10:00<\/a><\/p>\n<p>Source Domain: <a href=\"investingnews.com\">investingnews.com<\/a><\/p>\n<p>(TheNewswire)<\/p>\n<p> <span>Key Highlights<\/span> <\/p>\n<ul class=\"ee-ul\">\n<li>\n<p> <span><span>Positive First-in-Human Results:<\/span><\/span><span> Three-month Group 1 data met or exceeded expectations for safety, lens delivery, and vision performance.<\/span>\u00a0 <\/p>\n<\/li>\n<li>\n<p> <span><span>Major De-Risking Milestone:<\/span><\/span><span> The study successfully validated the core technology and cleared the path to the next clinical phase.<\/span>\u00a0 <\/p>\n<\/li>\n<li>\n<p> <span><span>Life-Changing Vision Improvements:<\/span><\/span><span> Patients with severe vision loss experienced meaningful improvements in everyday vision.<\/span>\u00a0 <\/p>\n<\/li>\n<li>\n<p> <span><span>Strong Forward Momentum:<\/span><\/span><span> Planning for Group 2 surgeries is underway, with lens and delivery enhancements already in development.<\/span>\u00a0 <\/p>\n<\/li>\n<li>\n<p> <span><span>High Confidence Going Forward:<\/span><\/span><span> Management remains fully confident in the Ocumetics accommodating intraocular lens platform following these results.<\/span>\u00a0 <\/p>\n<\/li>\n<\/ul>\n<p> <span>Calgary, Alberta \u2013 February 3, 2026<\/span><span> \u2013 <\/span><span>TheNewswire &#8211; <\/span><span>Ocumetics Technology Corp<\/span><span>.<\/span><span> (&#8220;Ocumetics&#8221; or the &#8220;Company&#8221;) (TSXV: OTC,OTC:OTCFF) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced positive three-month postoperative results from Group 1 patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens (the &#8220;Ocumetics Lens&#8221;). The results validate the Company&#8217;s core technology and represent a key clinical de-risking milestone as Ocumetics advances toward subsequent study phases.\u00a0<\/span> <\/p>\n<p> <span>The Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance &#8211; successfully achieving the primary objectives required to progress the clinical program.<\/span> <\/p>\n<p> <span>&#8220;These first-in-human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery, and strong visual outcomes,&#8221; said Dean Burns, President and CEO of Ocumetics. <\/span>\u00a0<span>&#8220;Following a detailed review of the data with Dr. Raphael Vasquez, our primary surgeon, I remain 100% confident in our accommodating intraocular lens technology. Based on this success, we have initiated planning for Group 2 surgeries.&#8221;<\/span> <\/p>\n<p> \u00a0 <\/p>\n<p>&#8230;<\/span><\/p>\n<p><a href=\"https:\/\/investingnews.com\/ocumetics-reports-positive-three-month-first-in-human-results-significantly-de-risking-its-accommodating-intraocular-lens-technology\/\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology https:\/\/investingnews.com\/ocumetics-reports-positive-three-month-first-in-human-results-significantly-de-risking-its-accommodating-intraocular-lens-technology\/&#8230;<\/p>\n","protected":false},"author":1,"featured_media":209515,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/investingnews.com\/media-library\/image.png?id=43003369&width=1200&height=600&coordinates=0%2C75%2C0%2C75","fifu_image_alt":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-209514","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/209514"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=209514"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/209514\/revisions"}],"predecessor-version":[{"id":209516,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/209514\/revisions\/209516"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/209515"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=209514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=209514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=209514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}